Imaging Prostate Cancer With Technetium-99m Tricarbonyl Finasteride Dithiocarbamate

In 2018, researchers modified finasteride to create a new compound, finasteride dithiocarbamate, and its rhenium and technetium-99m tricarbonyl complexes, to explore their potential as imaging agents for prostate cancer (PCa) in a rat model. The new compound was synthesized and its identity was confirmed through various analytical techniques. The technetium-99m labeled compound demonstrated high radiochemical purity and stability at room temperature and in serum. Preclinical studies showed that this compound had a high uptake in the prostate of rats with histopathologically confirmed PCa, suggesting its potential for noninvasive imaging of PCa in vivo.